Cost and access limit the number of people using GLP-1 drugs for weight loss, but health care experts said there are ways to make them more available and affordable to patients using both market-based and regulatory approaches
The FDA's guidance identifies several high-risk behaviors, such as starting patients on doses that far exceed approved levels, administering the medication more frequently than the recommended once-weekly schedule, and making dosage adjustments at intervals shorter than the four-week period advised
Se logran enfoques teraputicos ms fisiopatolgicos pero sobre todo permiten un manejo ms personalizado y ajustado a las caractersticas y riesgos individuales de los pacientes, privilegiando junto al control glicmico, la seguridad teraputica
Publisher | Google Scholor Diz-Chaves Y, Herrera-Prez S, Gonzlez-Matas LC, Lamas JA, Mallo F